HIV Scientific Papers

Pharmacokinetic profile of ibalizumab from a phase 3 trial.
2018
Kumar PN, Weinheimer S, Cohen Z, et al.
Poster #544 presented at: IDWeek; October 3-7 2018; San Francisco, California, USA.
Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection [abstract].
2018
Value in Health.
Brogan AJ, Talbird SE, Davis AE, et al.
21:S12. Proceedings of the Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2018.
Learn more
Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection.
2018
Brogan AJ, Talbird SE, Davis AE, et al.
Oral presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 19-23 2018; Baltimore, Maryland, USA.
Ibalizumab for the treatment of multidrug resistant (MDR) HIV-1 Infection.
2018
Emu B.
Oral presentation at: European Meeting on HIV & Hepatitis 2018; May 30-June 1 2018; Rome, Italy.
Ibalizumab: first global approval.
2018
Drugs.
Markham A.
78(7):781-785.
Learn more